NeuroSense Therapeutics (NRSN) Q2 2025 earnings summary

Executive summary

• Advanced PrimeC, a combination therapy for ALS, toward a pivotal Phase 3 trial following positive regulatory feedback and manufacturing scale-up.

• Regained Nasdaq compliance after a $5 million private placement, strengthening the balance sheet and shareholders' equity.

• Reported new long-term data from the Phase 2b PARADIGM study, showing significant slowing of ALS progression and improved survival metrics.

Financial highlights

• Research and development expenses decreased 32.9% year-over-year to $2.5 million for H1 2025, mainly due to reduced clinical activity.

• General and administrative expenses were $2.2 million, down 4.4% from H1 2024.

• Operating loss for H1 2025 was $4.7 million, compared to $6 million in H1 2024.

• Net loss for H1 2025 was $4.7 million, improving from a $6.3 million loss in H1 2024.

• Cash and cash equivalents at June 30, 2025, totaled $666,000, down from $3.4 million at year-end 2024.

Outlook and guidance

• Plans to submit a new NOC/c request in Canada for PrimeC, supported by additional data.

• Multinational Phase 3 trial of PrimeC in ALS expected to commence in H2 2025.

• Ongoing discussions with a global pharmaceutical partner may lead to a definitive commercialization agreement.